Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Tandem Diabetes Care (TNDM) Stock Price
News articles about Tandem Diabetes Care (NASDAQ:TNDM) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Tandem Diabetes Care earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news articles about the medical device company an impact score of 46.5750575713517 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Global Insulin Pumps (External) Strategic Business Report 2017 Featuring Leading Players – Debiotech, F. Hoffmann-La Roche, Insulet Medtronic Sooil Development & Tandem Diabetes Care Inc. – Research a (markets.financialcontent.com)
- $34.36 Million in Sales Expected for Tandem Diabetes Care, Inc. (TNDM) This Quarter (americanbankingnews.com)
- Trimble Inc., (NASDAQ: TRMB), Tandem Diabetes Care, Inc., (NASDAQ: TNDM), Waddell & Reed Financial, Inc … – Stocks In The News (press release) (tradingnewsnow.com)
- Tandem Diabetes Care, Inc. (TNDM) PT Lowered to $2.00 at Bank of America Corporation (americanbankingnews.com)
- Reviewing Zimmer Biomet Holdings (ZBH) and Tandem Diabetes Care (TNDM) (americanbankingnews.com)
Several research firms recently weighed in on TNDM. Robert W. Baird reissued a “hold” rating and set a $3.00 price target on shares of Tandem Diabetes Care in a research report on Sunday, November 19th. Zacks Investment Research raised Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $7.50 price target on the stock in a research report on Thursday, September 28th. Wedbush reissued an “outperform” rating and set a $17.00 price target (down from $50.00) on shares of Tandem Diabetes Care in a research report on Tuesday, October 10th. Finally, Piper Jaffray Companies reissued a “hold” rating and set a $15.00 price target on shares of Tandem Diabetes Care in a research report on Friday, October 6th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $11.29.
Tandem Diabetes Care (NASDAQ TNDM) traded up $0.05 during trading hours on Friday, reaching $2.71. The company had a trading volume of 55,648 shares, compared to its average volume of 573,493. Tandem Diabetes Care has a 52-week low of $2.15 and a 52-week high of $30.00. The company has a current ratio of 1.90, a quick ratio of 0.88 and a debt-to-equity ratio of -2.70.
Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Thursday, October 26th. The medical device company reported ($3.09) earnings per share for the quarter, beating the consensus estimate of ($3.74) by $0.65. The firm had revenue of $27.00 million for the quarter, compared to analyst estimates of $25.92 million. Tandem Diabetes Care had a negative return on equity of 1,177.11% and a negative net margin of 79.45%. Tandem Diabetes Care’s quarterly revenue was up 119.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.97) earnings per share. equities research analysts predict that Tandem Diabetes Care will post -15.37 EPS for the current year.
In other news, CEO Kim D. Blickenstaff bought 285,700 shares of the company’s stock in a transaction on Friday, October 13th. The shares were bought at an average cost of $3.50 per share, with a total value of $999,950.00. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 20.90% of the company’s stock.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Receive News & Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.